UBI PHARMA INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.9 TWD | -12.30% |
|
-27.03% | -59.88% |
| 04-18 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 634M 19.47M 1.56B | Sales 2023 | 649M 19.92M 1.59B | Capitalization | 4.1B 126M 10.06B |
|---|---|---|---|---|---|
| Net income 2022 | 47M 1.44M 115M | Net income 2023 | - 0 0 | EV / Sales 2022 | 8.97 x |
| Net Debt 2022 | 119M 3.66M 292M | Net Debt 2023 | 124M 3.82M 306M | EV / Sales 2023 | 6.51 x |
| P/E ratio 2022 |
116
x | P/E ratio 2023 |
3,465
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 27.77% |
More Fundamentals
* Assessed data
More news
| 1 day | -12.30% | ||
| 1 week | -27.03% | ||
| Current month | -50.53% | ||
| 1 month | -52.23% | ||
| 3 months | -58.69% | ||
| 6 months | -53.97% | ||
| Current year | -59.88% |
1 week
10.00
19.30
1 month
10.0030.00
Current year
10.0035.95
1 year
10.0042.54
3 years
10.00288.72
5 years
8.34288.72
10 years
8.34288.72
| Managers | Title | Age | Since |
|---|---|---|---|
Chi Hsiang Chen
CEO | Chief Executive Officer | - | 02/10/18 |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 10/04/16 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 28/02/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chi Hsiang Chen
CEO | Chief Executive Officer | - | 02/10/18 |
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Pai Feng Wu
PRN | Corporate Officer/Principal | - | 30/07/14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 13.9 | -12.30% | 2,051,385 |
| 25/04/24 | 15.85 | +15.69% | 2,792,125 |
| 24/04/24 | 13.7 | -1.79% | 2,649,284 |
| 23/04/24 | 13.95 | -11.99% | 7,921,550 |
| 22/04/24 | 15.85 | -16.80% | 3,165,588 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
UBI Pharma Inc is a Taiwan-based company mainly engaged in development and manufacturing of protein drugs and special dosage-form drugs. The Company is engaged in research and development, manufacturing and sales of protein drugs and special dosage-form drugs, contract manufacturing of pharmaceuticals, and provision of contract research services. The protein drug product line includes erythropoietin (UB-851) biosimilar drugs, innovative long-acting erythropoietin (UB-852), innovative long-acting granular ball community stimulating hormone (UB-853), and others used to treat anemia, neutropenia. The small molecule new drug product line includes B-Raf kinase inhibitor (UB-941) for the treatment of melanoma. The special scientific name drug product line includes tablets Olanzapine and Nevirapin for the treatment of schizophrenia and AIDS, and injections Granisetronl and Meropenen for the treatment of bacterial infections. It sells products in the domestic market and overseas markets.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -59.88% | 50.36M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 6562 Stock
